Sanofi Profit Beats Estimates as Blockbuster Drug Advances

Bloomberg2023-04-27

Sanofi’s profit rose more than expected in the first quarter as the French drugmaker’s blockbuster therapy Dupixent gained market share.Earnings per share were €2.16 ($2.39) excluding some items, the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104020425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-27 13:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104020425","market":"us","top_or_hot":-1,"title":"Sanofi Profit Beats Estimates as Blockbuster Drug Advances","media":"Bloomberg","content":"<div>\n<p>Sanofi’s profit rose more than expected in the first quarter as the French drugmaker’s blockbuster therapy Dupixent gained market share.Earnings per share were €2.16 ($2.39) excluding some items, the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-04-27/sanofi-profit-beats-estimates-as-blockbuster-drug-advances?srnd=premium\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Profit Beats Estimates as Blockbuster Drug Advances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Profit Beats Estimates as Blockbuster Drug Advances\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-27 13:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-04-27/sanofi-profit-beats-estimates-as-blockbuster-drug-advances?srnd=premium><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi’s profit rose more than expected in the first quarter as the French drugmaker’s blockbuster therapy Dupixent gained market share.Earnings per share were €2.16 ($2.39) excluding some items, the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-04-27/sanofi-profit-beats-estimates-as-blockbuster-drug-advances?srnd=premium\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"0O59.UK","symbol_name":"赛诺菲","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2023-04-27/sanofi-profit-beats-estimates-as-blockbuster-drug-advances?srnd=premium","article_id":"1104020425","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104020425","pubTimestamp":1682574846,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Sanofi’s profit rose more than expected in the first quarter as the French drugmaker’s blockbuster t","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"0O59.UK":"赛诺菲","SNY":"赛诺菲安万特"},"translate_title":"赛诺菲利润超过预期，重磅炸弹药物的进展","themeId":"ec9f6f0df2b6498587e7f5318b2eff2b","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"0O59.UK":0.9,"SNY":0.9},"content_text":"Sanofi’s profit rose more than expected in the first quarter as the French drugmaker’s blockbuster therapy Dupixent gained market share.Earnings per share were €2.16 ($2.39) excluding some items, the company said Thursday. That exceeded analysts’ €2 estimate.The French drugmaker is working to expand sales of Dupixent, a versatile antibody treatment for ailments ranging from asthma to severe eczema, while spending more to propel new medicines like Altuviiio for hemophilia and Beyfortus for respiratory syncytial virus in young children.  Sanofi is also hunting for new treatments as it anticipates falling sales for the aging multiple sclerosis drug Aubagio, which began facing cheaper competition in recent weeks. Last month, it agreed to buy Provention Bio for about $2.9 billion to gain a diabetes therapy recently approved in the US. Dupixent, already Sanofi’s best-seller with revenue expected to reach €10 billion this year, could get another boost if its use is expanded once more to include a chronic lung disorder. Altuviiio won US regulatory approval in February.Sanofi reiterated its guidance for 2023. Sales rose 5.7% to €10.2 billion last quarter. The stock has gained up about 14% this year, outperforming the Bloomberg index that tracks European drugmakers.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104020425"}